Abstract
Although St. Johns wort has been known for thousands of years and has been used for a variety of medicinal purposes, understanding of its activity and mechanisms of action is relatively new and not well understood. While researchers originally thought the naphthodianthrone hypericin was responsible for Hypericums antidepressant activity, it is now believed some other compound or a combination of constituents exerts their antidepressant activity on the body. Hypericum is unique in that it seems to impact all known neurotransmitters at some level, directly, or indirectly through receptor sensitivity and regulation. There has been a proliferation of clinical studies on Hypericum in the last ten years, and even though some of these studies might be methodologically flawed, the preponderance of the evidence proves Hypericum to be beneficial for the treatment of mild-to-moderate depression, with a very favorable side effect profile. One clinical trial carried out using two extracts with different hyperforin content indicate this constituent as (one of) the main active principle responsible for the antidepressant activity.
Keywords: Hypericum perforatum, Neuroactive Lead, naphthodianthrone, neurotransmitters
Current Topics in Medicinal Chemistry
Title: Hypericum perforatum, a Source of Neuroactive Lead Structures
Volume: 3 Issue: 2
Author(s): Luisella Verotta
Affiliation:
Keywords: Hypericum perforatum, Neuroactive Lead, naphthodianthrone, neurotransmitters
Abstract: Although St. Johns wort has been known for thousands of years and has been used for a variety of medicinal purposes, understanding of its activity and mechanisms of action is relatively new and not well understood. While researchers originally thought the naphthodianthrone hypericin was responsible for Hypericums antidepressant activity, it is now believed some other compound or a combination of constituents exerts their antidepressant activity on the body. Hypericum is unique in that it seems to impact all known neurotransmitters at some level, directly, or indirectly through receptor sensitivity and regulation. There has been a proliferation of clinical studies on Hypericum in the last ten years, and even though some of these studies might be methodologically flawed, the preponderance of the evidence proves Hypericum to be beneficial for the treatment of mild-to-moderate depression, with a very favorable side effect profile. One clinical trial carried out using two extracts with different hyperforin content indicate this constituent as (one of) the main active principle responsible for the antidepressant activity.
Export Options
About this article
Cite this article as:
Verotta Luisella, Hypericum perforatum, a Source of Neuroactive Lead Structures, Current Topics in Medicinal Chemistry 2003; 3 (2) . https://dx.doi.org/10.2174/1568026033392589
DOI https://dx.doi.org/10.2174/1568026033392589 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Commentary: (Research Highlights: “MiRNAcles” in Brain)
CNS & Neurological Disorders - Drug Targets Twitter Trends Reveals: Focus of Interest in the Sleep Trend Analytics on Response to COVID-19 Outbreak
Current Psychiatry Research and Reviews A Structural Approach into Human Tryptophan Hydroxylase and its Implications for the Regulation of Serotonin Biosynthesis
Current Medicinal Chemistry Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Editorial [Hot Topic: Naked Plasmid DNA for Gene Therapy (Guest Editors: Munehisa Shimamura & Ryuichi Morishita)]
Current Gene Therapy Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design The Ambivalence of Early Diagnosis – Returning Results in Current Alzheimer Research
Current Alzheimer Research Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Management of Impulse Control Disorders with Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Choice of Treatment with Antidepressants: Influencing Factors
Current Pharmaceutical Design Effects of Cissampelos sympodialis Eichl. and its Alkaloid, Warifteine, in an Experimental Model of Respiratory Allergy to Blomia tropicalis
Current Drug Targets Editorial [Hot topic: In Silico Approaches in G Protein-Coupled Receptors (GPCRs) Drug Discovery: Quo Vadis? (Executive Editor: Stefano Moro)]
Current Pharmaceutical Design Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Negative Affect and Drinking Drivers: A Review and Conceptual Model Linking Dissonance, Efficacy and Negative Affect to Risk and Motivation for Change
Current Drug Abuse Reviews Drug Candidates from Traditional Chinese Medicines
Current Topics in Medicinal Chemistry Systemic Injections of Primidone Cause Wake-Inducing Effects in Rats
Current Psychopharmacology